In this analysis of patients with myeloperoxidase-ANCA-positive AAV, all urinary complement C3 fragment levels were elevated significantly compared with healthy controls (P .01 for all). Specific ...

Fresh insight into the contribution of the complement pathway to degeneration in the brain has come from two new animal studies. The research shows that knockout of complement C3 protects against ...

Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug ...

HIGH POINT, N.C.--(BUSINESS WIRE)--High Point Clinical Trial Center (HPCTC) and Amyndas Pharmaceuticals jointly announce the completion of the AMY-101 First in Human (FIH) study, which assessed safety ...

University of Pennsylvania researchers have found a promising new treatment for periodontitis using a component of the immune system called complement, according to a new study in the Journal of ...

Complement 3 glomerulopathy (C3G) is diagnosed with a combination of a clinical evaluation, blood tests, urine tests, and a renal (kidney) biopsy. The only way to definitively diagnose C3G and its ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s ...

The results of a newly reported study may offer scientists a strategy for mitigating the negative side effects associated with intravenous injection of nanoparticles used in medicine. The new approach ...

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the ...

When told what to kill, the complement system deftly deals the final blows—helping the immune system purge away pathogens and infected cells. But in the nervous system, debate rages as to whether this ...

Cedric Francois, MD, PhD, Apellis Pharmaceuticals co-founder and CEO/President With its first FDA approval in hand for a complement inhibitor designed to treat paroxysmal nocturnal hemoglobinuria (PNH ...